Injectable PDRN products

Product Name: NanoFill Medium — medium-concentration purified polynucleotide biorevitalizer (20 mg/ml, 2%).

Overview: Baseline universal product for skin revitalization, quality improvement, dehydration treatment, and early aging signs; suitable for face/neck/decollete/hands/body.

Composition / Concentration: Purified polynucleotides 20 mg/ml; natural-origin DNA fragments 100–2000 bp; enzymatic deproteinization, purification, length fractionation, sterilization.

Pharmacological Action / Mechanism: Fibroblast proliferation; transition to myofibroblasts; collagen/elastin synthesis; free-radical binding/oxidative-stress reduction; dermal hydration via matrix water binding; post-laser/device recovery; ECM structure support.

Physical/Chemical Parameters: pH 6.8–7.2; viscosity 28–43 Pa·s; sterile isotonic gel.

Form / Packaging: Sterile syringes 2×3 ml or 10 ml vial.

Indications / Use Cases: Dehydration/barrier weakness; dullness/texture issues; early photoaging; reduced tone/elasticity; initial wrinkles/folds; post-acne minor scars; striae (as remodeling stimulator); pre-procedure skin priming; post-thermal recovery.

Areas & Injection Depth: Periorbital 0.5–1 mm (minimal volumes); cheeks/nasolabial 2–4 mm mid-dermis (linear-retrograde); neck/decollete 2–3 mm (small papules/short lines); hands/body (striae) 1.5–3 mm; bony boluses 6–12 mm in ligamentous zones (incl. McGregor point etc.).

Techniques: Micro-papules 0.02–0.05 ml (1–1.5 cm step); linear-retrograde 0.05–0.1 ml per line; ligament bolus—5 key points per side in midface; BAP-like 5 points/side 0.1–0.2 ml.

Recommended Dosages: Face ≈1.5 ml; neck/decollete/hands ≈3 ml; body (striae) up to 20 ml per area.

Treatment Course: 4 sessions, 1–2 weeks apart (preferably 5–15 days); maintenance every 3 months; scars/striae may require 5–6 sessions.

Combinations: RF microneedling; endolaser/endolifting (inject after heating); fractional lasers; HA fillers (2–3 weeks); peels (1–2 weeks); PRP, mesotherapy, microneedling.

Contraindications: Pregnancy/lactation; autoimmune conditions; acute dermatitis/infections; cancer; coagulation disorders; hypersensitivity; damaged skin in area.

Adverse Reactions: Typical transient—erythema, mild edema, tenderness, micro-hematomas, papules ≤48 h; rare—papules >48 h, allergic events.

Post-Procedure Care: Avoid sauna/sport/alcohol 24–48 h; SPF 50+; avoid massage; no cosmetics for first 12 h.

Practical Notes: Slow, low-pressure injection; periorbital—prefer cannula 25–27G; avoid vascular zones; adhere to safety; “before/after” photos, informed consent, course explanation advised.

Product Name: NanoFill Strong — high-concentration polynucleotide (PDRN) biostimulator (25 mg/ml).

Overview: Indicated for skin with pronounced degradation signs (reduced density/elasticity, wrinkles, scars, dryness, post-device depletion).

Composition / Concentration: Purified polynucleotides (PDRN) 25 mg/ml; DNA fragments 100–2000 bp; enzymatic deproteinization + multistep filtration.

Pharmacological Action / Mechanism: Fibroblast stimulation and conversion to myofibroblasts; increased collagen/elastin synthesis; free-radical binding; ECM hydration support; antioxidant and reparative effects; improved microcirculation and overall skin condition.

Physical/Chemical Parameters: Physiological pH 6.8–7.2; sterile gel with medium viscosity.

Form / Packaging: Sterile syringes 2×3 ml or 10 ml vial.

Indications / Use Cases: Dehydration/dullness; moderate–marked photoaging; reduced density/elasticity; wrinkles/folds/local atrophies; acne scars/striae; tissue priming before volumizing injections; recovery after thermal device procedures (laser, RF, endolifting); face/neck/decollete/hands/large body areas.

Areas & Injection Depth: Periorbital very superficial ~0.5–1 mm (small volumes); cheeks/nasolabial area mid-dermis ~2–4 mm (linear-retrograde); neck/decollete 2–3 mm (small papules/short lines); hands/body (incl. striae) 1.5–3 mm (even distribution); ligamentous boluses in midface 6–12 mm to bone.

Techniques: Micro-papules 0.02–0.05 ml per point (1–1.5 cm step); linear-retrograde 0.05–0.1 ml per line; bony boluses (pyramidal at support points incl. anatomical McGregor point); BAP-like 5 points per side 0.1–0.2 ml each.

Recommended Dosages: Face ~1.5–2 ml/session; neck/decollete/hands 2–3 ml; body/striae up to 20 ml within one area.

Treatment Course: 4 sessions with 1–2-week intervals (optimal 5–14 days); maintenance every 2–3 months; longer course for striae/scars.

Combinations: After thermal device work (supports remodeling); compatible with RF microneedling, endolaser/endolifting, fractional lasers; injectable combos with HA (interval 2–3 weeks), peels (1–2 weeks), PRP, mesotherapy.

Contraindications: Pregnancy/lactation; acute dermatoses/infections; autoimmune disorders; oncopathology; coagulation disorders; hypersensitivity; damaged skin at injection site.

Adverse Reactions: Usual transient reactions—erythema, mild edema, tenderness, micro-hematomas, papules 1–3 days; rarer >48 h reactions or allergic events.

Post-Procedure Care: Avoid sauna/sports/alcohol 24–48 h; SPF 50+; no massage unless clinically needed; avoid cosmetics on area for first 12 h.

Practical Notes: Inject slowly with minimal pressure; periorbital area preferably cannula 25–27G; avoid vascular zones and follow safety protocols; photo documentation and informed consent recommended.

Product Name: NanoFill MAX — very high-concentration polynucleotide gel (30 mg/ml).

Overview: For deep remodeling, structural dermal restoration, and pronounced chrono/photo-aging; final stage after Medium/Strong or standalone where strong biorestructuring is required.

Composition / Concentration: PDRN 30 mg/ml (highest in line); purified natural-origin DNA fragments; multistep deproteinization, filtration, sterilization, length standardization.

Pharmacological Action / Mechanism: Intensive fibroblast stimulation in deep dermis; collagen I, elastin, HA synthesis; density/architecture restoration; prolonged effect due to high DNA-polymer concentration; improved turgor/hydration/matrix compaction; antioxidant protection; biostimulation in high-tension zones (cheekbones, nasolabial area, jawline).

Physical/Chemical Parameters: Physiological pH 6.8–7.2; sterile gel with medium viscosity.

Form / Packaging: Sterile syringes 2×3 ml or 10 ml vial.

Indications / Use Cases: Marked loss of density/turgor; mid-to-deep laxity; tissue architecture disruption (“self-heavy”/“nambe-type aging”); static wrinkles/folds; facial “shadowing” from matrix deficit; deformational aging; post-device/laser recovery; intimate-zone atrophy; pronounced androgenic hair loss (as part of tricho-protocol).

Areas & Injection Depth: Cheekbones/cheeks/midface—subdermal/deep dermal; nasolabial folds—point/short linear; jawline/chin—deep dermis; neck/decollete—linear-retrograde (cannula); intimate zone—submucosal, linear or bolus in low-tone areas; scalp—micro-papules (dermal).

Techniques: Cannula 25–27G (38–50 mm): linear-retrograde, fan, subdermal for cheekbones/jawline/neck; Needle 27–30G: bolus for nasolabial/deep wrinkles, point technique for high-tension zones, micro-papules for scalp; Layered (Medium → Strong → MAX as deep final); Blanching thin uniform placement for full-face structural revitalization without volume.

Recommended Dosages: Face 1.5–3 ml/session; cheekbones 0.5–1.0 ml/side; nasolabial 0.2–0.5 ml; neck/decollete 1.5–3 ml; intimate zone 2–3 ml/session; scalp 1–2 ml (dose depends on tissue severity and age).

Treatment Course: Layered protocol—Medium (1–2 sessions) → Strong (1 session) → MAX (final, deepest); repeat MAX after 10–15 days if needed; maintenance every 3–6 months; standalone MAX: 2–3 sessions (10–15-day interval); duration of effect 6–9 months.

Combinations: Endolifting (inject 7–14 days later); CO₂/erbium/non-ablative lasers; RF microneedling; Medium/Strong; PRP, amino-acid cocktails; HA fillers (2–3 weeks).

Contraindications: Pregnancy/lactation; acute inflammatory/infectious processes; autoimmune disease; cancer; coagulation disorders; allergy; damaged skin at injection site.

Adverse Reactions: Usual—erythema, mild edema, tenderness, bruising; transient compaction 1–3 days; rare—papules >48 h, local hypersensitivity.

Post-Procedure Care: Avoid heat/sport/alcohol/pool 24–48 h; SPF 50+; no massage without indications; no cosmetics first 12 h.

Practical Notes: Slow placement, especially in deep structural zones; cannula reduces hematoma risk and aids “difficult” areas; suited for lifting/restructuring without adding volume; key for pronounced chronological aging.

Product Name: NanoFill BODY — large-volume polynucleotide gel for extensive body areas.

Overview: Designed for deep revitalization, densification, and elasticity improvement on large body surfaces, including low-tone areas or post-weight-change skin; 50 ml vial enables economical, technical coverage of wide zones.

Composition / Concentration: Purified polynucleotides 25 mg/ml.

Pharmacological Action / Mechanism: Fibroblast proliferation in body dermis; collagen/elastin/HA synthesis; increased density/turgor across large areas; reduced laxity/atony; improved hydration/texture; oxidative-stress reduction; post-device regeneration.

Physical/Chemical Parameters: Physiological pH 6.8–7.2; sterile gel with medium viscosity.

Form / Packaging: Sterile large syringe/vial 50 ml (single or multiple uses depending on area size).

Indications / Use Cases: Loss of density on large areas; laxity/low turgor; postpartum changes; post-weight fluctuations; photoaging/dehydration; striae (dermal remodeling stimulator); post-device recovery (RF/lasers); correction for neck, decollete, arms, abdomen, thighs, buttocks.

Areas & Injection Depth: Neck/decollete 1.5–3 mm (linear or small papules); arms (inner) 1.5–3 mm even; abdomen 2–4 mm linear-retrograde or grid; thighs 2–4 mm (striae or general laxity); buttocks 2–4 mm (density); striae 1.5–3 mm even.

Techniques: Micro-papules 0.02–0.1 ml/point (1–2 cm spacing); linear-retrograde 0.05–0.2 ml/line; grid (cross-lines 1–2 cm) for abdomen/thighs/arms; cannula 25–27G (38–50 mm) for lax zones; needle or cannula depending on dermal thickness.

Recommended Dosages: Neck/decollete 5–10 ml; arms 5–10 ml; abdomen 10–20 ml; thighs 10–20 ml per area; buttocks 10–20 ml; striae 5–20 ml depending on area.

Treatment Course: 3–5 sessions at 10–20-day intervals (by tissue status); maintenance every 3–6 months; extensive laxity may require 6–8 sessions.

Combinations: RF lifting (mono/multipolar); body endolifting; fractional lasers (after 10–14 days); ultrasound SMAS (in preparation phase); meso-cocktails and PRP; HA skin-boosters for deep hydration.

Contraindications: Pregnancy/lactation; acute bacterial/viral infections; autoimmune disease; coagulation disorders; cancer; allergy; active skin damage.

Adverse Reactions: Typical transient—erythema, mild edema, tenderness, small hematomas, papules ≤48 h; rare—persistent papules, local hypersensitivity.

Post-Procedure Care: Avoid sauna/sport/heat 24–48 h; SPF on exposed areas; no massage; moisturize as directed.

Practical Notes: Enables economical, even coverage of large surfaces; prefer cannula where bruise risk is higher; slow, pressure-controlled injection; combine techniques (papules + grid) for striae/laxity; effect builds steadily, especially after 3–5 sessions.

Product Name: NanoFill EYES — specialized injectable for the peri-orbital zone.

Overview: For dark circles, shadows, fine lines, puffiness, and chronically fatigued peri-orbital tissues; formulated on PDRN with hydration and light dermal recovery support; suitable for thin skin, chronic stress of tissues, low vascularization, microcirculation issues.

Composition / Concentration: PDRN (2% ≈ 20 mg/ml, like Medium) adapted for delicate injection; low-molecular-weight hyaluronic acid; antioxidant complex; vitamin micro-fraction (C, B5); peptide stabilizing complex (microcirculation activation); syringe 2–3 ml sterile blister.

Pharmacological Action / Mechanism: PDRN—fibroblast proliferation, myofibroblast activation, dermal density improvement, oxidative-stress reduction (key in dark circles), micro-relief smoothing; LMW-HA—elasticity/hydration without edema risk, improved light reflectance; antioxidants/peptides—reduced pigmentation intensity, brighter color, vascular stabilization.

Physical/Chemical Parameters: Physiological pH 6.8–7.2; sterile gel with medium viscosity.

Form / Packaging: Sterile syringe 2–3 ml (blister).

Indications / Use Cases: Dark circles/shadows; vascular bluish discoloration; fine lines (“crow’s feet”); tired look; chronic dehydration; thin skin with lost density; peri-orbital aging prevention.

Areas & Injection Depth: Very superficial or mid-dermis; avoid large vessels and lateral vascular network; minimal volumes medially; cannula 25–27G preferred under the eye.

Techniques: Micro-papules 0.01–0.02 ml (0.5–1 cm step); linear-retrograde for tear trough with 25–27G cannula 0.05–0.1 ml/line; fan vectors to lateral canthus; point placement for dark circles 0.01–0.02 ml.

Recommended Dosages: Whole peri-orbital zone 0.5–1 ml; pronounced dark circles up to 1 ml (over two sessions); lateral canthus 0.1–0.2 ml; tear trough 0.05–0.1 ml.

Treatment Course: Standard 4 sessions at 10–14-day intervals; for marked dark circles—6 sessions (every 7–10 days); maintenance every 6–8 weeks.

Combinations: Endolaser/endolifting (PDRN after thermal step); RF microneedling (after 10 days); soft fillers via cannula (after 2–3 weeks); light-therapy (LED, IPL); low-strength peels; general PN protocols (MAX/Medium); not on the same day as aggressive device work.

Contraindications: Pregnancy/lactation; age <18; active infections/dermatitis; edema-prone patients (caution); severe vascular disorders; autoimmune disease; cancer; individual sensitivity.

Adverse Reactions: Typical—mild edema ≤24 h, erythema, tenderness, micro-bruises; rare—edema >24–48 h, persistent papules, medial bruising.

Post-Procedure Care: Avoid heat/sport/sauna 24–48 h; SPF 50; do not rub/massage; no cosmetics <12 h; cold compresses for sensitivity.

Practical Notes: Use minimal doses—peri-orbita is not for “filling”; avoid injections during fluid-retention days; cannula significantly reduces bruising risk; PDRN effect is delayed (3–4 weeks after course); repeated courses yield cumulative “dense/bright” under-eye skin.

Product Name: NanoFill HAIR — injectable biotechnological cocktail for hair loss management and scalp recovery.

Overview: For men/women with diffuse/shedding, stress-related alopecia, androgenetic alopecia (adjunct), seasonal loss, and overall hair depletion.

Composition / Concentration: PDRN 2% ≈ 20 mg/ml; low-molecular HA; vitamins (A, C, B5, B12); glutathione; peptides (Acetyl Hexapeptide-8 + biopeptide complex); amino-acid matrix; 3 ml sterile syringe.

Pharmacological Action / Mechanism: PDRN—scalp regeneration, perfollicular inflammation reduction, reparative cell activation, longer anagen; peptides/amino acids—stimulate follicular activity and protein synthesis, improve density/thickness; vitamins—cellular energy recovery, barrier stabilization, brittleness reduction; HA—hydration and trophic support.

Physical/Chemical Parameters: Physiological pH 6.8–7.2; sterile gel with medium viscosity.

Form / Packaging: 3 ml syringe (sterile blister).

Indications / Use Cases: Diffuse alopecia (men/women); androgenetic alopecia I–III (as part of combination); seasonal loss; stress alopecia; brittleness/thinning; slow growth; dull/weak hair; scalp hypoxia; microcirculation disorders.

Areas & Injection Depth: Scalp dermis 1–3 mm; micro-papules or “stamping” grid; cannula allowed for large areas.

Techniques: Micro-papules 0.02–0.05 ml/point (1–1.5 cm step); linear 0.05 ml/line in severe thinning; cannula 25–27G for rapid large-area spread; spot injections 0.01–0.02 ml for focal thinning.

Recommended Dosages: Standard area (vertex/crown) 1–2 ml; full scalp 3 ml; male androgenetic zone 1–1.5 ml; local correction 0.5 ml.

Treatment Course: 6–8 sessions every 7–10 days; for persistent loss—10 weekly sessions then maintenance every 3–4 weeks; first effect after 2–3 sessions; stable result 4–6 weeks post-course.

Combinations: PRP/PRF (alternate weekly); scalp microneedling 0.5–1 mm; LED (red); laser alopecia protocols; minoxidil (topical/systemic); finasteride/dutasteride (as indicated); ozone therapy; avoid same-day deep chemical peels or aggressive lasers.

Contraindications: Pregnancy/lactation; cancer; autoimmune dermatoses; scalp infections; coagulation disorders; allergy; active dermatitis/psoriasis in area.

Adverse Reactions: Typical—erythema 12–24 h, burning 30–60 min, micro-bruises, mild tenderness; rare—local edema, papules >48 h, reactive folliculitis.

Post-Procedure Care: No hair washing 24 h; avoid sport/sauna/overheating 48 h; avoid alcohol 24 h; no aggressive products 3–5 days; LED accelerates effect.

Practical Notes: PDRN reduces inflammatory component (key in stress loss); cumulative effect—each session reinforces prior; feasible even in dense hair; androgenetic alopecia needs hormonal combo; avoid mid-course gaps; technique should be quick and superficial (≤3 mm).

Product Name: NanoFill PINCO ROSSO — injectable biorevitalizing gel for vaginal mucosal restoration.

Overview: For deep restoration of vaginal mucosa, elasticity, tone, comfort, and metabolic activity; combines PDRN and vitamin B12 to drive regeneration, improve trophics, moisturize mucosa, and restore structure; for age-related changes, postpartum, dryness/atrophy/low tone, and post-device recovery (laser, RF, endolifting).

Composition / Concentration: PDRN 2% ≈ 20 mg/ml; Vitamin B12 (cyanocobalamin); hyaluronic acid; sterile syringe 2–3 ml.

Pharmacological Action / Mechanism: PDRN—mucosal cellular regeneration, epithelial-dermal restoration, elasticity/density increase, dryness/micro-cracks reduction, collagenogenesis enhancement, moisture/pH normalization; Vitamin B12—metabolic activation, improved perfusion, faster post-device recovery, tone/sensitivity improvement, dryness/discomfort reduction; HA—immediate mucosal hydration, viscoelastic improvement, tissue firmness support.

Physical/Chemical Parameters: Physiological pH 6.8–7.2; sterile gel with medium viscosity.

Form / Packaging: Sterile 2–3 ml syringe.

Indications / Use Cases: Vaginal atrophy (menopause/postpartum); dryness/discomfort/hypo-sensitivity; reduced vaginal wall elasticity; pre-laser/RF/endolifting preparation; post-device support; mild stress urinary incontinence; chronic mucosal trauma/inflammation; post-intense delivery changes.

Areas & Injection Depth: Inner vaginal wall—anterior/posterior/lateral; level: superficial submucosa; depth 2–4 mm.

Techniques: Micro-papules 0.02–0.05 ml (1 cm step) evenly along treated length; linear 0.05 ml/line for elasticity loss; cannula 25–27G for even distribution/low trauma/full-channel reach; bolus 0.05–0.1 ml at focal atrophy points.

Recommended Dosages: Standard revitalization 2–3 ml; postpartum 3 ml; pre-device 1–2 ml; maintenance 1–2 ml.

Treatment Course: Start 1–2 sessions (7–10-day interval); final 1–2 sessions (7–14 days later); maintenance every 3–6 months; first effect 5–7 days; stable result 3–4 weeks.

Combinations: Vaginal laser therapy; RF rejuvenation; endolifting; PDRN Medium/Strong/Max (sandwich protocol); stress-incontinence treatments (adjunct); avoid same-day aggressive chemical peels or intensive thermal devices.

Contraindications: Pregnancy/lactation; active infections; cancer; autoimmune vaginal diseases; coagulation disorders; allergy; active vaginitis/colpitis.

Adverse Reactions: Typical—burning 10–30 min, mild edema ≤24 h, 1–2 days discomfort; rare—papules >48 h, local edema, chronic inflammation flare.

Post-Procedure Care: Abstain from sexual intercourse 48 h; avoid overheating 48 h; no tampons 24–48 h; no swimming pool 48 h; avoid aggressive products 3–5 days.

Practical Notes: Ideal final step after laser; cannula ensures even full-length effect; PDRN markedly reduces dryness/discomfort; may serve as standalone therapy for atrophy; cumulative improvement with each session; patients often report quality-of-life gains after first injection.